Your browser is no longer supported. Please, upgrade your browser.
Settings
NVCR NovoCure Limited daily Stock Chart
NVCR [NASD]
NovoCure Limited
Index- P/E- EPS (ttm)-0.83 Insider Own0.80% Shs Outstand87.91M Perf Week-2.14%
Market Cap1.81B Forward P/E- EPS next Y-0.03 Insider Trans-54.81% Shs Float69.20M Perf Month-5.94%
Income-72.90M PEG- EPS next Q-0.11 Inst Own48.90% Short Float5.11% Perf Quarter13.50%
Sales153.60M P/S11.79 EPS this Y58.00% Inst Trans-9.36% Short Ratio4.10 Perf Half Y8.71%
Book/sh1.31 P/B15.73 EPS next Y95.60% ROA-27.30% Target Price27.00 Perf Year188.11%
Cash/sh2.12 P/C9.70 EPS next 5Y60.00% ROE-57.70% 52W Range6.75 - 24.15 Perf YTD1.98%
Dividend- P/FCF- EPS past 5Y- ROI-52.70% 52W High-17.70% Beta-
Dividend %- Quick Ratio5.30 Sales past 5Y- Gross Margin66.80% 52W Low194.44% ATR1.01
Employees460 Current Ratio5.90 Sales Q/Q130.90% Oper. Margin-34.30% RSI (14)39.59 Volatility4.06% 4.89%
OptionableYes Debt/Eq0.83 EPS Q/Q67.10% Profit Margin-47.40% Rel Volume1.56 Prev Close20.60
ShortableYes LT Debt/Eq0.83 EarningsFeb 22 BMO Payout- Avg Volume861.29K Price19.88
Recom1.80 SMA20-8.03% SMA50-5.68% SMA2005.79% Volume390,684 Change-3.52%
Feb-23-18Reiterated Mizuho Buy $25 → $28
May-24-17Upgrade Wells Fargo Market Perform → Outperform
Jul-29-16Reiterated Wedbush Outperform $30 → $20
Jan-19-16Initiated Barclays Underweight $16
Dec-02-15Initiated Deutsche Bank Hold $28
Oct-27-15Initiated Wedbush Outperform
Oct-27-15Initiated JP Morgan Overweight
Oct-27-15Initiated JMP Securities Mkt Outperform $43
Feb-22-18 07:30AM  NovoCure reports 4Q loss Associated Press
06:00AM  Novocure Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Company Update Business Wire
06:00AM  Novocure Ltd. to Host Earnings Call ACCESSWIRE
Feb-13-18 05:19PM  Who Really Owns NovoCure Limited (NASDAQ:NVCR)? Simply Wall St.
Feb-09-18 07:55AM  Report: Exploring Fundamental Drivers Behind Vector Group, NovoCure, ORBCOMM, Adamis Pharmaceuticals, Calumet Specialty Products Partners, and Lakeland New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Feb-07-18 04:01PM  Novocure Secures New $150 Million Non-Dilutive Term Loan Financing Business Wire
Feb-05-18 08:31AM  Minerva Neurosciences Names Remy Luthringer as Executive Chairman and William Doyle as Lead Independent Director GlobeNewswire
Feb-01-18 11:05AM  JAMA Oncology Publishes EF-14 Pivotal Trial Analysis Showing Optune Plus Temozolomide Improved Survival without Negatively Influencing Health-Related Quality of Life Compared to Temozolomide Alone in Newly Diagnosed GBM Patients Business Wire
Jan-16-18 06:15PM  Novocure Ltd (NVCR) CEO Asaf Danziger Sold $7.5 million of Shares GuruFocus.com
Jan-09-18 10:53AM  Here's Why NovoCure Popped 157% in 2017 Motley Fool
07:30AM  Novocure Announces Fourth Quarter and Full Year 2017 Operating Statistics and Preliminary Revenue Business Wire
Dec-21-17 06:25PM  Is NovoCure Limiteds (NASDAQ:NVCR) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
06:00AM  3 Stocks That Could Put Amazon's Returns to Shame Motley Fool
Dec-20-17 07:30AM  Novocure to Participate in 36th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-19-17 11:05AM  JAMA Publishes Final Analysis of EF-14 Phase 3 Pivotal Trial of Optune® Together with Temozolomide Demonstrating Unprecedented Survival Results for Newly Diagnosed Glioblastoma Business Wire
Dec-18-17 07:37AM  Novocure Receives FDA IDE Approval for its PANOVA 3 Phase 3 Pivotal Clinical Trial in Advanced Pancreatic Cancer Business Wire
Dec-13-17 12:44PM  How Does NovoCure Limiteds (NASDAQ:NVCR) EPS Growth Stack Up Against Industry Performance? Simply Wall St.
Dec-11-17 08:17AM  Minerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors GlobeNewswire
08:15AM  Minerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors GlobeNewswire
Dec-07-17 02:25PM  ETFs with exposure to Novocure Ltd. : December 7, 2017 Capital Cube
Dec-04-17 11:28AM  Novocure Ltd. Value Analysis (NASDAQ:NVCR) : December 4, 2017 Capital Cube -6.89%
11:20AM  Is NovoCure Limited (NVCR) Undervalued? Simply Wall St.
Dec-01-17 07:30AM  Novocure Receives Reimbursement Approval for Optune® in Japan for the Treatment of Newly Diagnosed Glioblastoma Business Wire
07:13AM  Novocure Ltd. breached its 50 day moving average in a Bullish Manner : NVCR-US : December 1, 2017 Capital Cube
Nov-22-17 07:30AM  Novocure to Present at Two Upcoming Investor Conferences in December Business Wire
Nov-20-17 08:20AM  Investor Expectations to Drive Momentum within Vector Group, NovoCure, ORBCOMM, Ecolab, Bank of America, and Viking Therapeutics Discovering Underlying Factors of Influence GlobeNewswire
Nov-18-17 11:32AM  3 Top Medical Device Stocks to Buy Now Motley Fool
Nov-17-17 09:34AM  Estimating The Intrinsic Value Of NovoCure Limited (NVCR) Simply Wall St.
09:26AM  Novocure Shares Jump on Phase 3 Data Analysis -- Biotech Movers TheStreet.com
07:30AM  Patients Who Used Optune® More Than 90 Percent of the Time Had the Greatest Chance of Survival in Novocures EF-14 Trial: A Median Survival of 24.9 Months from Randomization and a Five-Year Survival of 29.3 Percent Business Wire
Nov-13-17 12:56PM  ETFs with exposure to Novocure Ltd. : November 13, 2017 Capital Cube
07:19AM  Novocure Announces 28 Presentations on Tumor Treating Fields from Externally Led Clinical Research and Analysis at 22nd Annual Meeting of the Society for Neuro-Oncology Business Wire
Nov-09-17 07:00AM  Novocure Announces 10 Presentations on Simulation Studies Aiming to Optimize Treatment Delivery of Tumor Treating Fields at 22nd Annual Meeting of the Society for Neuro-Oncology Business Wire
Nov-08-17 07:00AM  Novocure Announces 13 Preclinical Presentations Highlighting Data on Tumor Treating Fields Mechanism of Action at 22nd Annual Meeting of the Society for Neuro-Oncology Business Wire -6.13%
Nov-06-17 10:00AM  3 Stocks Changing the Future of Healthcare Motley Fool
07:00AM  Novocure Announces Six Clinical Presentations on Novocures Phase 3 Pivotal EF-14 Trial Data in Newly Diagnosed Glioblastoma at 22nd Annual Meeting of the Society for Neuro-Oncology Business Wire
Nov-01-17 12:16PM  Harry Boxers four stocks to watch this week MarketWatch
Oct-31-17 08:09AM  Novocure Ltd. breached its 50 day moving average in a Bullish Manner : NVCR-US : October 31, 2017 Capital Cube +6.14%
Oct-30-17 12:07PM  ETFs with exposure to Novocure Ltd. : October 30, 2017 Capital Cube
Oct-27-17 06:06PM  Edited Transcript of NVCR earnings conference call or presentation 26-Oct-17 12:00pm GMT Thomson Reuters StreetEvents +5.71%
09:18AM  Novocure Ltd. :NVCR-US: Earnings Analysis: Q3, 2017 By the Numbers : October 27, 2017 Capital Cube
Oct-26-17 06:45AM  NovoCure reports 3Q loss Associated Press
06:00AM  Novocure Reports Third Quarter 2017 Financial Results and Provides Company Update Business Wire
Oct-22-17 12:15PM  3 Healthcare Stocks for Your Radar Motley Fool
Oct-17-17 08:45AM  NovoCure (NVCR) Looks Good: Stock Adds 8.3% in Session Zacks
Oct-16-17 04:30PM  Why Rite Aid, Hudbay Minerals, and NovoCure Jumped Today Motley Fool +8.28%
07:30AM  Novocure Announces Data Presentations at the IASLC 18th World Conference on Lung Cancer Business Wire
Oct-03-17 11:53AM  Novocure Ltd. Value Analysis (NASDAQ:NVCR) : October 3, 2017 Capital Cube
Oct-02-17 08:22AM  Novocure Ltd. breached its 50 day moving average in a Bearish Manner : NVCR-US : October 2, 2017 Capital Cube
07:00AM  Novocure to Report Third Quarter 2017 Financial Results Business Wire
Sep-25-17 09:40AM  Intercept Spikes; Novocure Jumps on Phase 3 Data -Biotech Movers TheStreet.com
Sep-24-17 06:15PM  Combination of Optune® with Temozolomide Demonstrates Unprecedented Five-Year Survival for Newly Diagnosed Glioblastoma Patients Business Wire
Sep-22-17 07:00AM  Novocure Announces Data Presentations at the American Society for Radiation Oncologys 2017 Annual Meeting Business Wire
Sep-19-17 07:15AM  3 Innovation-Forward Healthcare Stocks to Buy Now Motley Fool
Sep-14-17 02:29PM  Dolby Laboratories is a stock to watch after Apples new iPhone launch MarketWatch
Sep-06-17 07:00AM  Novocure Announces Data Presentations at the ESMO 2017 Congress Business Wire
Sep-05-17 07:41AM  German Federal Joint Committee Announces Decision to Support a Clinical Trial to Study Optune® for the Treatment of Newly Diagnosed Glioblastoma Business Wire
Aug-28-17 08:23AM  If You Love Intuitive Surgical, You Should Check Out This Small-Cap Growth Stock Motley Fool
Aug-24-17 07:00AM  Novocure to Present at Two Upcoming Investor Conferences in September Business Wire
Aug-22-17 02:21PM  Edited Transcript of NVCR earnings conference call or presentation 27-Jul-17 12:00pm GMT Thomson Reuters StreetEvents
Aug-16-17 06:00AM  3 Stocks That Could Soar More Than Priceline Motley Fool
Aug-15-17 09:01PM  3 Game-Changing Small-Cap Healthcare Stocks Motley Fool
Aug-11-17 06:10PM  ETFs with exposure to Novocure Ltd. : August 11, 2017 Capital Cube
Aug-08-17 09:25AM  Novocure Announces National Reimbursement for Optune® in Austria Business Wire +5.23%
Aug-02-17 05:31PM  3 Exciting Biotechs Under $30: Novocure Is Revolutionizing Brain Cancer Treatment Motley Fool
07:00AM  Novocure to Present at the 2017 Wedbush PacGrow Healthcare Conference Business Wire
Jul-31-17 10:07AM  3 Hot Healthcare Stocks Under $30 Motley Fool
Jul-28-17 12:38PM  Novocure Ltd. :NVCR-US: Earnings Analysis: Q2, 2017 By the Numbers : July 28, 2017 Capital Cube
12:28AM  NovoCure reports 2Q loss Associated Press
Jul-27-17 06:15AM  Investor Network: Novocure Ltd. to Host Earnings Call ACCESSWIRE +5.97%
06:00AM  Novocure Reports Second Quarter 2017 Financial Results and Provides Company Update Business Wire
Jul-24-17 07:22AM  Novocure Announces a Phase 1b Clinical Trial to Evaluate the Safety of Marizomib and Temozolomide in Combination with Optune® as Adjuvant Therapy in Patients with Glioblastoma Business Wire
Jul-20-17 06:21PM  Many treatment options, most experimental, available to John McCain Reuters
Jul-18-17 08:16AM  These 2 Companies Have No Competition Motley Fool
Jul-13-17 06:07AM  The Fastest Growing Cancer Company You've Never Heard Of Motley Fool
Jul-12-17 08:47AM  NovoCure (NVCR) Jumps: Stock Rises 10.5% Zacks
08:20AM  Today's Research Reports on Stocks to Watch: Amicus Therapeutics, Inc. and NovoCure Ltd. Accesswire
07:30AM  Novocures Optune® Now Available at More Than 600 Cancer Treatment Centers in the U.S. Business Wire
Jul-11-17 06:03PM  Why Novocure Shares Jumped 10.5% Today Motley Fool +10.50%
07:30AM  Data on Delivery of Tumor Treating Fields to be Presented at the 39th Annual International Conference of the IEEE Engineering in Medicine and Biology Society Business Wire
06:20AM  Warren Buffett Has the Edge Over Paul Singer, Oncor CEO Tells TheStreet's Jim Cramer on 'Mad Money' TheStreet.com
Jul-10-17 07:45PM  Cramer Remix: Not just fun and games, this stock is the r... CNBC Videos
06:59PM  Cramer Remix: Not just fun and games, this stock is the real deal CNBC
Jun-30-17 08:38AM  Is NovoCure (NVCR) a Great Growth Stock? Zacks
07:00AM  Novocure to Report Second Quarter 2017 Financial Results Business Wire
Jun-28-17 08:47AM  Novocure to Present Three Abstracts on Tumor Treating Fields and Pancreatic Cancer at the European Society for Medical Oncology 19th World Congress on Gastrointestinal Cancer Business Wire
Jun-13-17 04:30PM  Novocure Announces Change to Presentation Time at the JMP Securities 2017 Life Sciences Conference Business Wire
Jun-08-17 06:30AM  First Patient Enrolled in RTOG Trial of Optune® together with Bevacizumab for Patients with Bevacizumab-Refractory Recurrent Glioblastoma Business Wire
Jun-05-17 07:00AM  Health Care Service Corporation Issues Positive Coverage Decision for Optune Business Wire
Jun-02-17 08:13AM  3 Stocks That Could Double Your Money Motley Fool
07:30AM  Novocure to Present at the JMP Securities 2017 Life Sciences Conference Business Wire
May-24-17 11:19AM  Shark Bites: Focus on the 'Little Picture' TheStreet.com +12.50%
May-15-17 07:25AM  Novocure Receives Humanitarian Use Device Designation for Treatment of Pleural Mesothelioma Business Wire
May-11-17 08:12AM  Martin J. Madden Joins Novocure Board of Directors Business Wire
May-08-17 07:00AM  Combination of Optune with Standard of Care Chemotherapy, Temozolomide, Delayed Decline in Several Health-Related Quality of Life Scales Compared to Temozolomide Alone for Newly Diagnosed Glioblastoma Patients Business Wire +5.93%
May-04-17 07:00AM  Novocure Announces Opening of Two Pilot Trials to Evaluate the Use of TTFields for Pediatric Gliomas Business Wire
May-01-17 07:50PM  Edited Transcript of NVCR earnings conference call or presentation 27-Apr-17 12:00pm GMT Thomson Reuters StreetEvents
04:12PM  ETFs with exposure to Novocure Ltd. : May 1, 2017 Capital Cube
07:30AM  Novocure to Present at Three Upcoming Investor Conferences in May Business Wire
07:25AM  Novocure Announces Data Presentations at the World Federation of Neuro-oncology Societies 5th Quadrennial Meeting Business Wire
Markets a wearable electric field device for treating glioblastoma brain cancer.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ambrogi Michael J.Chief Operating OfficerFeb 06Option Exercise0.2350,00011,50074,087Feb 08 04:14 PM
Longsworth Todd ChristopherGeneral CounselJan 29Option Exercise6.7211,63078,15416,628Jan 31 04:29 PM
Longsworth Todd ChristopherGeneral CounselJan 29Sale24.0011,630279,1204,998Jan 31 04:29 PM
Danziger AsafChief Executive OfficerJan 29Sale24.0213,974335,588356,790Jan 31 04:22 PM
Danziger AsafChief Executive OfficerJan 25Sale22.436,456144,840370,764Jan 26 04:14 PM
Danziger AsafChief Executive OfficerJan 24Sale22.1710,600235,007377,220Jan 25 04:26 PM
Danziger AsafChief Executive OfficerJan 23Sale22.0310,248225,794387,820Jan 25 04:26 PM
DOYLE WILLIAM FExecutive ChairmanJan 22Option Exercise3.591,5495,56192,746Jan 24 04:18 PM
Danziger AsafChief Executive OfficerJan 16Sale22.2014,900330,755398,068Jan 17 05:05 PM
Danziger AsafChief Executive OfficerJan 12Sale22.0222,895504,237412,968Jan 16 05:00 PM
Kirson Eilon D.Chief Science OfficerJan 11Sale22.0025,320557,1263,181Jan 16 05:01 PM
Danziger AsafChief Executive OfficerJan 11Sale22.35313,5257,007,503435,863Jan 16 05:00 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerJan 09Sale21.0231,132654,376209,078Jan 10 04:11 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerJan 04Sale21.0326,264552,314239,900Jan 05 04:06 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerJan 03Sale21.002,60454,689266,164Jan 05 04:06 PM
Palti YoramChief Technology OfficerNov 13Sale17.1330,000513,8701,431,054Nov 14 04:25 PM
Palti YoramChief Technology OfficerNov 10Sale17.6130,000528,1501,461,054Nov 13 04:36 PM
Palti YoramChief Technology OfficerNov 09Sale18.2530,000547,4331,491,054Nov 13 04:36 PM
Palti YoramChief Technology OfficerNov 08Sale19.6130,000588,2491,521,054Nov 13 04:36 PM
Palti YoramChief Technology OfficerNov 07Sale20.4230,000612,5201,551,054Nov 08 04:17 PM
Palti YoramChief Technology OfficerNov 06Sale21.7130,000651,2401,581,054Nov 08 04:17 PM
Kirson Eilon D.Chief Science OfficerNov 06Sale22.009,100200,20028,501Nov 08 04:15 PM
Danziger AsafChief Executive OfficerNov 06Sale22.006,919152,218749,105Nov 08 04:14 PM
Kirson Eilon D.Chief Science OfficerNov 03Sale22.003,10068,20037,601Nov 06 04:18 PM
Palti YoramChief Technology OfficerNov 03Sale21.6630,000649,6801,611,054Nov 06 04:22 PM
Danziger AsafChief Executive OfficerNov 03Sale22.002,30050,600756,024Nov 06 04:15 PM
Ambrogi Michael J.Chief Operating OfficerNov 03Sale22.0090019,80024,087Nov 06 04:17 PM
Ambrogi Michael J.Chief Operating OfficerNov 02Sale22.003006,60024,987Nov 06 04:17 PM
Palti YoramChief Technology OfficerNov 02Sale21.7830,000653,5201,641,054Nov 06 04:22 PM
Kirson Eilon D.Chief Science OfficerNov 02Sale22.003006,60040,701Nov 06 04:18 PM
Danziger AsafChief Executive OfficerNov 01Sale22.0115,716345,870758,324Nov 02 04:20 PM
Kirson Eilon D.Chief Science OfficerNov 01Sale22.0122,119486,81041,001Nov 02 04:22 PM
Ambrogi Michael J.Chief Operating OfficerNov 01Sale22.0124,227533,16425,287Nov 02 04:19 PM
Ambrogi Michael J.Chief Operating OfficerOct 31Sale22.001002,20049,514Nov 02 04:19 PM
Kirson Eilon D.Chief Science OfficerOct 31Sale22.001503,30063,120Nov 02 04:22 PM
Danziger AsafChief Executive OfficerOct 31Sale22.001503,300774,040Nov 02 04:20 PM
Danziger AsafChief Executive OfficerSep 25Sale22.0590019,845774,190Sep 27 04:18 PM
Danziger AsafChief Executive OfficerSep 14Sale22.001,77238,984775,090Sep 15 04:05 PM
Danziger AsafChief Executive OfficerSep 13Sale22.0135,500781,518776,862Sep 15 04:05 PM
Danziger AsafChief Executive OfficerJul 14Option Exercise0.38354,780134,816812,362Jul 18 04:48 PM
Danziger AsafChief Executive OfficerJul 11Sale19.957,383147,325457,582Jul 13 04:14 PM
Danziger AsafChief Executive OfficerJul 10Sale18.08203,9003,685,900464,965Jul 11 04:22 PM
Danziger AsafChief Executive OfficerJul 07Sale18.0370,4591,270,658668,865Jul 11 04:22 PM
Danziger AsafChief Executive OfficerJul 06Sale18.095,05091,344739,324Jul 07 04:33 PM
Danziger AsafChief Executive OfficerJul 05Sale18.14155,0882,813,917744,374Jul 07 04:33 PM
Pomona Capital VII, L.P.10% OwnerJun 26Sale17.4699,3411,734,1862,741,925Jun 27 04:11 PM
Pomona Capital VII, L.P.10% OwnerJun 23Sale17.34973,19116,872,8942,772,870Jun 27 04:11 PM
Kirson Eilon D.Chief Science OfficerJun 21Sale16.7866,3611,113,206222,722Jun 22 04:29 PM
Kirson Eilon D.Chief Science OfficerJun 19Sale15.0615,000225,885289,083Jun 21 04:19 PM
Danziger AsafChief Executive OfficerJun 19Sale15.51124,7201,934,906896,917Jun 21 04:17 PM
Danziger AsafChief Executive OfficerJun 16Sale15.029,212138,3461,021,637Jun 19 04:31 PM
Danziger AsafChief Executive OfficerJun 15Sale15.1933,245504,8921,030,849Jun 19 04:31 PM
DOYLE WILLIAM FDirectorJun 14Option Exercise3.596,49823,32891,197Jun 15 04:23 PM
Danziger AsafChief Executive OfficerJun 14Sale15.015,40281,0681,064,094Jun 15 04:17 PM
Kirson Eilon D.Chief Science OfficerJun 13Sale15.019,044135,769304,083Jun 15 04:28 PM
Danziger AsafChief Executive OfficerJun 13Sale15.2388,7001,351,0781,069,496Jun 15 04:17 PM
Danziger AsafChief Executive OfficerJun 12Sale15.095,10076,9341,158,196Jun 13 06:35 PM
Kirson Eilon D.Chief Science OfficerJun 12Sale15.085,95689,828313,127Jun 13 06:19 PM
Kirson Eilon D.Chief Science OfficerJun 09Sale15.0215,000225,225319,083Jun 13 06:19 PM
Danziger AsafChief Executive OfficerJun 09Sale15.13175,5012,654,9791,163,296Jun 13 06:35 PM
Palti YoramChief Technology OfficerJun 05Sale13.823,82552,8420Jun 06 05:17 PM
Palti YoramChief Technology OfficerJun 02Sale13.494,00053,9563,825Jun 05 04:19 PM
Palti YoramChief Technology OfficerJun 01Sale13.054,00052,1847,825Jun 05 04:19 PM
Palti YoramChief Technology OfficerMay 31Sale12.474,00049,89211,825Jun 01 04:29 PM
Palti YoramChief Technology OfficerMay 30Sale12.504,00050,00415,825Jun 01 04:29 PM
Palti YoramChief Technology OfficerMay 26Sale12.864,00051,44019,825May 30 05:08 PM
Palti YoramChief Technology OfficerMay 25Sale12.894,00051,56423,825May 30 05:08 PM
Palti YoramChief Technology OfficerMay 24Sale13.154,00052,61227,825May 25 04:21 PM
Palti YoramChief Technology OfficerMay 23Sale11.804,00047,20031,825May 24 04:31 PM
Palti YoramChief Technology OfficerMay 22Sale11.674,00046,67635,825May 24 04:31 PM
Palti YoramChief Technology OfficerMay 19Sale11.544,00046,14439,825May 22 04:14 PM
Palti YoramChief Technology OfficerMay 18Sale11.244,00044,95643,825May 22 04:14 PM
Palti YoramChief Technology OfficerMay 17Sale11.474,00045,88447,825May 18 05:52 PM
Palti YoramChief Technology OfficerMay 16Sale11.904,00047,60451,825May 17 04:14 PM
Palti YoramChief Technology OfficerMay 15Sale12.194,00048,75655,825May 17 04:14 PM
Palti YoramChief Technology OfficerMay 10Sale12.254,00048,99267,825May 11 04:04 PM
Palti YoramChief Technology OfficerMay 09Sale12.334,00049,30871,825May 11 04:04 PM
Palti YoramChief Technology OfficerMay 08Sale12.094,00048,37675,825May 09 04:03 PM
Palti YoramChief Technology OfficerMay 05Sale11.554,00046,20079,825May 09 04:03 PM
Palti YoramChief Technology OfficerMay 04Sale11.294,00045,14483,825May 05 04:05 PM
Palti YoramChief Technology OfficerMay 03Sale11.554,00046,21687,825May 05 04:05 PM
Palti YoramChief Technology OfficerMay 02Sale11.844,00047,34491,825May 03 04:05 PM
Palti YoramChief Technology OfficerMay 01Sale11.444,00045,77695,825May 03 04:05 PM
Palti YoramChief Technology OfficerApr 28Sale11.294,00045,16099,825May 01 04:07 PM
Palti YoramChief Technology OfficerApr 27Sale11.214,00044,820103,825May 01 04:07 PM
Palti YoramChief Technology OfficerApr 26Sale10.784,00043,100107,825Apr 27 04:05 PM
Palti YoramChief Technology OfficerApr 25Sale10.794,00043,164111,825Apr 27 04:05 PM
Palti YoramChief Technology OfficerApr 24Sale11.064,00044,244115,825Apr 25 04:05 PM
Palti YoramChief Technology OfficerApr 21Sale11.454,00045,804119,825Apr 25 04:05 PM
Palti YoramChief Technology OfficerApr 20Sale11.464,00045,820123,825Apr 21 04:05 PM
Palti YoramChief Technology OfficerApr 19Sale11.034,00044,132127,825Apr 21 04:05 PM
Palti YoramChief Technology OfficerApr 18Sale10.644,00042,556131,825Apr 19 04:09 PM
Palti YoramChief Technology OfficerApr 17Sale10.774,00043,076135,825Apr 19 04:09 PM
Palti YoramChief Technology OfficerApr 13Sale10.434,00041,724139,825Apr 19 04:09 PM
Palti YoramChief Technology OfficerApr 12Sale10.724,00042,864143,825Apr 19 04:09 PM
Perlhagen Gert L.DirectorMar 14Buy6.93125,000866,2506,125,000Mar 16 04:06 PM
DOYLE WILLIAM FExecutive ChairmanFeb 28Option Exercise3.591,212,4544,352,71020,024,052Mar 02 07:21 PM